We are a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. In 2009, through a series of strategic initiatives and workforce and cost reductions, we restructured our organization and are now focused on developing and commercializing a limited number of products, which we believe have substantial therapeutic and commercial potential and in which we retain a significant ownership position. Our current portfolio includes one commercial product, RECOTHROM®
![Zymogenetics logo](https://files.capedge.com/DEF%2014A/0001193125-06-087167/g43750g06e56.jpg)
Company profile
Ticker
ZGEN
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
911144498
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Oct 10
EFFECT
Notice of effectiveness
18 Oct 10
EFFECT
Notice of effectiveness
18 Oct 10
POS AM
Prospectus update (post-effective amendment)
14 Oct 10
POS AM
Prospectus update (post-effective amendment)
14 Oct 10
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 10
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 10
25-NSE
Exchange delisting
12 Oct 10
8-K
Termination of a Material Definitive Agreement
12 Oct 10
SC TO-T/A
Third party tender offer statement (amended)
8 Oct 10